{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:30:47Z","timestamp":1791199847776,"version":"4.2.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,29]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Triple oral therapy combining metformin, sodium-glucose cotransporter 2 inhibitor, and a dipeptidyl peptidase-4 inhibitor has been proposed as a synergistic approach to intensify glycemic control in patients with type 2 diabetes mellitus. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of triple therapy compared to dual therapy (metformin plus either sodium-glucose cotransporter 2 or dipeptidyl peptidase-4 inhibitor).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Following preferred reporting items for systematic review and meta-analysis guidelines, we searched PubMed, Embase, Scopus, and Web of Science through January 2026. Studies included randomized controlled trials comparing triple versus dual therapy in adults with type 2 diabetes mellitus. Outcomes included hemoglobin A1c (HbA1c), fasting plasma glucose, body weight, achievement of HbA1c\u2005&lt;\u20057%, and adverse events (AEs). Pooled standardized mean differences (SMDs) and risk ratios (RRs) were calculated using random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eight studies encompassing 2606 participants were included. Findings indicate triple therapy significantly reduced HbA1c levels compared to dual therapy, with a SMD of\u2005\u2212\u20050.54 (95% confidence interval [CI]: \u22120.92 to\u2005\u22120.16;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.005). Triple therapy resulted in greater reduction in fasting plasma glucose, with an SMD of\u2005\u22120.30 (95% CI: \u22120.62 to 0.01;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.06). Patients on triple therapy were more likely to achieve HbA1c levels below 7% (RR: 2.02; 95% CI: 1.55\u20132.63;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001). Weight reduction was modest, with an SMD: \u22120.14 (95% CI: \u22120.22 to\u2005\u22120.07;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0002). No significant differences were found in total AEs (RR\u2005=\u20050.97;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.69) or hypoglycemia (RR\u2005=\u20051.32;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.32), although there was higher discontinuation due to AEs (RR\u2005=\u20052.62;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Triple therapy offers superior glycemic control over dual therapy without major safety trade-offs, though tolerability may affect long-term adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049050","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:05:32Z","timestamp":1780074332000},"page":"e49050","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Triple oral therapy combining metformin, SGLT-2 and DPP-4 inhibitors versus dual therapy in type 2 diabetes mellitus: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Abdul Fatah","family":"Malik","sequence":"first","affiliation":[{"name":"Department of Medicine, Bilawal Medical College, LUMHS, Jamshoro, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Kashish","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Shivani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ascension Saint Jospeh Hospital, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Khairpur Medical College, Khairpur Mir\u2019s, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesha","family":"Kumari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Haseeb","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Mujtaba","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat National Hospital and Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Raheem","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baqai Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad Sinaan","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Liaquat National Hospital and Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Saleh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dow International Medical College, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3942-9554","authenticated-orcid":false,"given":"Tagwa Kalool Fadlalla","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ahfad University of Women, Omdurman, Sudan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260827","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"R2-20260827","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"R3-20260827","doi-asserted-by":"crossref","first-page":"109021","DOI":"10.1016\/j.jdiacomp.2025.109021","article-title":"SGLT-2 inhibitors on cardiac autonomic function in individuals with and without type 2 diabetes mellitus.","volume":"39","author":"\u00d6zel","year":"2025","journal-title":"J Diabetes Complications"},{"key":"R4-20260827","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2522\/ptj.20080020","article-title":"Epidemiology of diabetes and diabetes-related complications.","volume":"88","author":"Deshpande","year":"2008","journal-title":"Phys Ther"},{"key":"R5-20260827","doi-asserted-by":"crossref","first-page":"e35285","DOI":"10.1097\/MD.0000000000035285","article-title":"Vascular complications of diabetes: a narrative review.","volume":"102","author":"Lu","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R6-20260827","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pcd.2022.02.002","article-title":"2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care.","volume":"16","author":"Seidu","year":"2022","journal-title":"Prim Care Diabetes"},{"key":"R7-20260827","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy.","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R8-20260827","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4239\/wjd.v9.i12.209","article-title":"Treatment approach to type 2 diabetes: past, present and future.","volume":"9","author":"Blaslov","year":"2018","journal-title":"World J Diabetes"},{"key":"R9-20260827","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/1753-0407.13316","article-title":"Temporal trends in patients with peripheral artery disease influenced by diabetes mellitus in Germany.","volume":"14","author":"Schmitt","year":"2022","journal-title":"J Diabetes"},{"key":"R10-20260827","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(12)60769-7","article-title":"Type 2 diabetes: which drug as add-on to metformin?","volume":"379","author":"Madsbad","year":"2012","journal-title":"Lancet"},{"issue":"Supplement_1","key":"R11-20260827","first-page":"S181","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes \u2013 2025.","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"key":"R12-20260827","doi-asserted-by":"crossref","first-page":"e2983","DOI":"10.1002\/dmrr.2983","article-title":"Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials.","volume":"34","author":"Meng","year":"2018","journal-title":"Diabetes Metab Res Rev"},{"key":"R13-20260827","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","article-title":"Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R14-20260827","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1464-5491.2011.03425.x","article-title":"Time trends in absolute and modifiable coronary heart disease risk in patients with Type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003\u20132008.","volume":"29","author":"Fh\u00e4rm","year":"2012","journal-title":"Diabet Med"},{"key":"R15-20260827","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/cpt.70087","article-title":"Ocular complications of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors in T2DM treatments: a retrospective real-world cohort study.","volume":"119","author":"Lin","year":"2026","journal-title":"Clin Pharmacol Ther"},{"key":"R16-20260827","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/dc10-2251","article-title":"Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999\u20132008.","volume":"34","author":"Ford","year":"2011","journal-title":"Diabetes Care"},{"key":"R17-20260827","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jfma.2019.08.035","article-title":"Prevalence of diabetic macrovascular complications and related factors from 2005 to 2014 in Taiwan: a nationwide survey.","volume":"118","author":"Lee","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"R18-20260827","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.amjmed.2010.11.003","article-title":"Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?","volume":"124","author":"Zinman","year":"2011","journal-title":"Am J Med"},{"key":"R19-20260827","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4158\/EP161725.RA","article-title":"Sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibition: promise of a dynamic duo.","volume":"23","author":"Lingvay","year":"2017","journal-title":"Endocr Pract"},{"key":"R20-20260827","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12872-024-04442-5","article-title":"Sodium-glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes mellitus: a meta-analysis.","volume":"25","author":"Liang","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"R21-20260827","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1038\/s41598-018-22658-2","article-title":"Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.","volume":"8","author":"Min","year":"2018","journal-title":"Sci Rep"},{"key":"R22-20260827","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4239\/wjd.v13.i2.85","article-title":"Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment.","volume":"13","author":"Florentin","year":"2022","journal-title":"World J Diabetes"},{"key":"R23-20260827","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","article-title":"Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).","volume":"23","author":"Thornberry","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R24-20260827","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2337\/dc15-0779","article-title":"Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes.","volume":"38","author":"Mathieu","year":"2015","journal-title":"Diabetes Care"},{"key":"R25-20260827","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10741-017-9617-4","article-title":"DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.","volume":"22","author":"Xia","year":"2017","journal-title":"Heart Fail Rev"},{"key":"R26-20260827","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"R27-20260827","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1111\/dom.16550","article-title":"Efficacy and safety of combination therapy using SGLT-2 and DPP-4 inhibitors to treat type 2 diabetes: an updated systematic review and meta\u2010analysis with focus on an Asian subpopulation.","volume":"27","author":"Kim","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"R28-20260827","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"R29-20260827","doi-asserted-by":"crossref","first-page":"108054","DOI":"10.1016\/j.diabres.2020.108054","article-title":"Treatment paradigm shifting implications of recent cardiovascular outcome trials: core insights on the brink of the 2020ies.","volume":"161","author":"Standl","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"R30-20260827","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.","volume":"9","author":"Marx","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R31-20260827","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-022-01575-9","article-title":"Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes.","volume":"21","author":"Davies","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R32-20260827","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12417","article-title":"Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT): a randomized trial.","volume":"17","author":"Abdul-Ghani","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"R33-20260827","first-page":"320","article-title":"Efficacy and safety of triple therapy with SGLT-2 inhibitor, DPP-4 inhibitor, and metformin in type 2 diabetes: a meta-analysis.","volume":"29","author":"Li","year":"2023","journal-title":"Altern Ther Health Med"},{"key":"R34-20260827","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/dom.13394","article-title":"Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial.","volume":"20","author":"Han","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R35-20260827","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/dom.13194","article-title":"Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial.","volume":"20","author":"Pratley","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R36-20260827","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12325-024-03037-y","article-title":"Efficacy of dapagliflozin\u2009+\u2009sitagliptin\u2009+\u2009Metformin versus sitagliptin\u2009+\u2009Metformin in T2DM inadequately controlled on metformin monotherapy: a multicentric randomized trial.","volume":"42","author":"Singh","year":"2025","journal-title":"Adv Ther"},{"key":"R37-20260827","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/a-0664-7583","article-title":"Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes.","volume":"128","author":"Ram\u00edrez-Rodr\u00edguez","year":"2020","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"R38-20260827","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function.","volume":"100","author":"Merovci","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-20260827","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4158\/EP161323.OR","article-title":"Combined treatment with saxagliptin plus dapagliflozin reduces insulin levels by increased insulin clearance and improves \u03b2-cell function.","volume":"23","author":"Ekholm","year":"2017","journal-title":"Endocr Pract"},{"key":"R40-20260827","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/dom.13594","article-title":"Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.","volume":"21","author":"Handelsman","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R41-20260827","first-page":"49","article-title":"Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia.","volume":"65","author":"Joaqui","year":"2021","journal-title":"Arch Endocrinol Metab"},{"key":"R42-20260827","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4093\/dmj.2023.0128","article-title":"Two-year therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and empagliflozin in drug-na\u00efve type 2 diabetes mellitus patients.","volume":"48","author":"Park","year":"2024","journal-title":"Diabetes Metab J"},{"key":"R43-20260827","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial.","volume":"40","author":"S\u00f8fteland","year":"2017","journal-title":"Diabetes Care"},{"key":"R44-20260827","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin.","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications"},{"key":"R45-20260827","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications"},{"key":"R46-20260827","first-page":"231","article-title":"Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.","volume":"25","author":"Pawaskar","year":"2019","journal-title":"Am J Manag Care"},{"key":"R47-20260827","doi-asserted-by":"crossref","first-page":"e0250993","DOI":"10.1371\/journal.pone.0250993","article-title":"Regimen simplification and medication adherence: fixed-dose versus loose-dose combination therapy for type 2 diabetes.","volume":"16","author":"B\u00f6hm","year":"2021","journal-title":"PLoS One"},{"key":"R48-20260827","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1007\/s12325-023-02523-z","article-title":"Fixed-dose combination of dapagliflozin\u2009+\u2009sitagliptin\u2009+\u2009Metformin in patients with type 2 diabetes poorly controlled with metformin: phase 3, randomized comparison with dual combinations.","volume":"40","author":"Sahay","year":"2023","journal-title":"Adv Ther"},{"issue":"Suppl 2","key":"R49-20260827","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.2337\/dcS13-2035","article-title":"Guideline approach to therapy in patients with newly diagnosed type 2 diabetes.","volume":"36","author":"Raz","year":"2013","journal-title":"Diabetes Care"},{"key":"R50-20260827","doi-asserted-by":"crossref","first-page":"e1461","DOI":"10.7717\/peerj.1461","article-title":"Triple therapy in type 2 diabetes; a systematic review and network meta-analysis.","volume":"3","author":"Downes","year":"2015","journal-title":"PeerJ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:00:15Z","timestamp":1787828415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":50,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049050","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"2025-08-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}